There will be a big pps spike when it does due to the massive revenue potential of acute respiratory diagnosis for all age demographic in the US whereas only commercialisation can increase RSH's pps now as the market has factor in the limit market for wheezo for the US, Europe and Australia.
And RSH was FDA approved as "Substantially Equivalent"? And wheezo is only approved as a Class I medical device for CE and TGA......
There will be a big pps spike when it does due to the massive...
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RSH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $38.54M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 800000 | 2.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.0¢ | 508500 | 3 |
View Market Depth
| Last trade - 16.12pm 11/09/2024 (20 minute delay) ? |
| RSH (ASX) Chart |
Day chart unavailable